164 results on '"Lasa, Marta"'
Search Results
2. A CD38/CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐CD38 monoclonal antibodies.
3. Maturation of NAA20 Aminoterminal End Is Essential to Assemble NatB N-Terminal Acetyltransferase Complex
4. N-terminal acetylation mutants affect alpha-synuclein stability, protein levels and neuronal toxicity
5. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
6. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
7. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
8. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
9. O181 / #829 - VASCULAR AND CIRCULATING BLOOD EXPOSURE TO PROTON OR PHOTON IRRADIATION: DIFERENTIALS IN LYMPHOPENIA METRICS
10. Supplementary Figure 3 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
11. Supplementary Figure 4 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
12. Supplementary Figure 5 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
13. Supplementary Figure 1 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
14. Supplementary Figure 2 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
15. CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell
16. Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
17. N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB
18. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies.
19. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
20. Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
21. Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies
22. A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent in Multiple Myeloma Patients Relapsed and/or Refractory (RRMM) to Anti-CD38 Monoclonal Antibodies (mAbs)
23. Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)
24. Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)
25. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis
26. Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)
27. Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment
28. Chiral-at-metal ruthenium(II) complexes as catalysts in the asymmetric cyclopropanation reaction
29. Synthesis of the four stereoisomers of cyclobutane analogues of phenylalanine in enantiomerically pure form
30. Synthesis of enantiomerically pure cis- and trans-cyclopentane analogues of phenylalanine
31. Aspartame analogues containing 1-amino-2-phenylcyclohexanecarboxylic acids (c 6Phe). Part 2
32. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
33. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
34. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
35. The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
36. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
37. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis
38. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
39. Understanding the Cellular Origin and Pathogenic Transcriptional Programs in Multiple Myeloma (MM) and Light-Chain Amyloidosis (AL) through the Dissection of the Normal Plasma Cell (PC) Development
40. Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS and Multiple Myeloma (MM)
41. Genetic Profiling and Novel Recurrent Chromosomal Alterations in Patients with Light Chain Amyloidosis
42. NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma
43. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis
44. High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM)
45. Critical Analysis on the Mechanism of Action (MoA) of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma (MM)
46. New Insights into the Mechanism of Action (MoA) of First-in-Class IgG-Based Bcma T-Cell Bispecific Antibody (TCB) for the Treatment of Multiple Myeloma (MM)
47. Pre-Clinical Efficacy of the Anti-CD38 Monoclonal Antibody (mAb) Isatuximab in Acute Myeloid Leukemia (AML)
48. Image analysis for the quantitative comparison of stress fibers and focal adhesions
49. Image Analysis for the Quantitative Comparison of Stress Fibers and Focal Adhesions
50. Synthesis of enantiomerically pure 1-amino-2-phenylcycloalkanecarboxylic acids (cnPhe)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.